USD 1
↑ 0.0419 (4.37%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| OCGN | 4.4 | -8.3 | 5.3 | -21.9 | -41.2 | 167.4 | -88.0 | 75.4 | -99.9 | -99.9 |
| S&P 500 | -0.6 | -0.5 | 1.5 | 9.1 | 13.4 | 32.3 | 27.0 | 92.1 | 191.7 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | OCGN |
| name | Ocugen, Inc. |
| price | 1 |
| changes percentage | 4.3732 |
| change | 0.0419 |
| day low | 0.95 |
| day high | 1.08 |
| year high | 2.105 |
| year low | 0.36 |
| market cap | 287858000 |
| price avg 50 | 1.01964 |
| price avg 200 | 1.281035 |
| exchange | NASDAQ |
| volume | 4743908 |
| avg volume | 3586014 |
| open | 0.9711 |
| previous close | 0.9581 |
| eps | -0.18 |
| pe | -5.56 |
| earnings announcement | 2024-11-08T05:00:00.000+0000 |
| shares outstanding | 287858000 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001372299 | |||
| revenue | 6036000 | 2488000 | 142.60 |
| gross profit | -33537000 | 1415000 | -2470.11 |
| gross profit ratio | -5.56 | 0.57 | -1076.94 |
| research and development expenses | 39573000 | 49757000 | -20.47 |
| operating expenses | 71567000 | 84868000 | -15.67 |
| interest income | 0 | 1400000 | -100.00 |
| interest expense | 0 | 0 | NaN |
| ebitda | -64827000 | -88591000 | 26.82 |
| ebitdaratio | -10.74 | -34.11 | 68.51 |
| operating income | -65531000 | -84868000 | 22.78 |
| operating income ratio | -10.86 | -34.11 | 68.17 |
| net income | -63078000 | -77834000 | 18.96 |
| net income ratio | -10.45 | -31.28 | 66.60 |
| eps | -0.26 | -0.36 | 27.78 |
Revenue Growth: revenue increased to 6 million in 2023 from 2 million in 2022 representing a change of 142.6%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 72 million in 2023 from 85 million in 2022 representing a change of -15.67%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -0.26 in 2023 from -0.26 in 2022 representing a change of 27.78%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -34 million in 2023 from 1 million in 2022 representing a change of -2470.11%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 40 million in 2023 from 50 million in 2022 representing a change of -20.47%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -65 million in 2023 from -89 million in 2022 representing a change of 26.82%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -66 million in 2023 from -85 million in 2022 representing a change of 22.78%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -63 million in 2023 from -78 million in 2022 representing a change of 18.96%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001372299 | |||
| revenue | 1141000 | 1014000 | 12.52 |
| gross profit | -7761000 | 835000 | -1029.46 |
| gross profit ratio | -6.8 | 0.82 | -926.01 |
| research and development expenses | 8902000 | 6826000 | 30.41 |
| operating expenses | 16590000 | 13051000 | 27.12 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | 0 | NaN |
| ebitda | -14871000 | -12037000 | -23.54 |
| ebitdaratio | -13.03 | -11.87 | -9.79 |
| operating income | -15449000 | -12216000 | -26.47 |
| operating income ratio | -13.54 | -12.05 | -12.39 |
| net income | -15280000 | -11924000 | -28.14 |
| net income ratio | -13.39 | -11.76 | -13.88 |
| eps | -0.04 | -0.05 | 13.79 |
Revenue Growth: revenue increased to 1 million in 2024Q2 from 1 million in 2024Q1 representing a change of 12.52%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 9 million in 2024Q2 from 7 million in 2024Q1 representing a change of 30.41%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -15 million in 2024Q2 from -12 million in 2024Q1 representing a change of -23.54%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -15 million in 2024Q2 from -12 million in 2024Q1 representing a change of -26.47%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -15 million in 2024Q2 from -12 million in 2024Q1 representing a change of -28.14%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.04 in 2024Q2 from -0.04 in 2024Q1 representing a change of 13.79%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -8 million in 2024Q2 from 1 million in 2024Q1 representing a change of -1029.46%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 17 million in 2024Q2 from 13 million in 2024Q1 representing a change of 27.12%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001372299 | |||
| total assets | 64547000 | 108632000 | -40.58 |
| total liabilities | 23983000 | 24580000 | -2.43 |
| total equity | 40564000 | 84052000 | -51.74 |
| cash and cash equivalents | 39462000 | 77563000 | -49.12 |
| short term investments | 0 | 13371000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 42971000 | 98492000 | -56.37 |
| total non current assets | 21576000 | 10140000 | 112.78 |
| total current liabilities | 17089000 | 18460000 | -7.43 |
| total non current liabilities | 6894000 | 6120000 | 12.65 |
| common stock | 2567000 | 2217000 | 15.79 |
| retained earnings | -286167000 | -213018000 | -34.34 |
| total debt | 6941000 | 6374000 | 8.90 |
Total Assets: Total Assets decreased to 65 million in 2023 from 109 million in 2022 representing a change of -40.58%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 41 million in 2023 from 84 million in 2022 representing a change of -51.74%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 39 million in 2023 from 78 million in 2022 representing a change of -49.12%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 13 million in 2022 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 43 million in 2023 from 98 million in 2022 representing a change of -56.37%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -286 million in 2023 from -213 million in 2022 representing a change of -34.34%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 7 million in 2023 from 6 million in 2022 representing a change of 8.9%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 24 million in 2023 from 25 million in 2022 representing a change of -2.43%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 17 million in 2023 from 18 million in 2022 representing a change of -7.43%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 3 in 2023 from 2 in 2022 representing a change of 15.79%. This indicates an increase in ownership interest.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001372299 | |||
| total assets | 40542000 | 51794000 | -21.72 |
| total liabilities | 23615000 | 21533000 | 9.67 |
| total equity | 16927000 | 30261000 | -44.06 |
| cash and cash equivalents | 15697000 | 26375000 | -40.49 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 18617000 | 29998000 | -37.94 |
| total non current assets | 21925000 | 21795999 | 0.59 |
| total current liabilities | 17972000 | 16050000 | 11.98 |
| total non current liabilities | 5643000 | 5483000 | 2.92 |
| common stock | 2576000 | 2575000 | 0.04 |
| retained earnings | -313371000 | -298091000 | -5.13 |
| total debt | 6865000 | 6832000 | 0.48 |
Total Assets: Total Assets decreased to 41 million in 2024Q2 from 52 million in 2024Q1 representing a change of -21.72%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 24 million in 2024Q2 from 22 million in 2024Q1 representing a change of 9.67%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 17 million in 2024Q2 from 30 million in 2024Q1 representing a change of -44.06%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 16 million in 2024Q2 from 26 million in 2024Q1 representing a change of -40.49%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 19 million in 2024Q2 from 30 million in 2024Q1 representing a change of -37.94%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 18 million in 2024Q2 from 16 million in 2024Q1 representing a change of 11.98%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -313 million in 2024Q2 from -298 million in 2024Q1 representing a change of -5.13%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 7 million in 2024Q2 from 7 million in 2024Q1 representing a change of 0.48%. This indicates an increase in overall debt burden.
Common Stock: Common Stock increased to 3 in 2024Q2 from 3 in 2024Q1 representing a change of 0.04%. This indicates an increase in ownership interest.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001372299 | |||
| net change in cash | -38101000 | -17546000 | -117.15 |
| operating cash flow | -62054000 | -60079000 | -3.29 |
| free cash flow | -72530000 | -64536000 | -12.39 |
| capital expenditure | -10476000 | -4457000 | -135.05 |
| depreciation and amortization | 704000 | 480000 | 46.67 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 9217000 | 10541000 | -12.56 |
| accounts payables | 0 | 9487000 | -100.00 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -10476000 | -4457000 | -135.05 |
| net cash used for investing activites | 3077000 | -16967000 | 118.14 |
| debt repayment | 500000 | 500000 | 0.00 |
| common stock issued | 20804000 | 59567000 | -65.07 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 20881000 | 59475000 | -64.89 |
| cash at end of period | 39462000 | 77563000 | -49.12 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 77563000 | 95109000 | -18.45 |
Net Change in Cash: Net Change in Cash decreased to -38 million in 2023 from -18 million in 2022 representing a change of -117.15%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -62 million in 2023 from -60 million in 2022 representing a change of -3.29%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -73 million in 2023 from -65 million in 2022 representing a change of -12.39%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -10 million in 2023 from -4 million in 2022 representing a change of -135.05%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 9 million in 2023 from 11 million in 2022 representing a change of -12.56%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 9 million in 2022 representing a change of -100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001372299 | |||
| operating cash flow | -9911000 | -10595000 | 6.46 |
| free cash flow | -10424000 | -12947000 | 19.49 |
| capital expenditure | -513000 | -2352000 | 78.19 |
| depreciation and amortization | 578000 | 179000 | 222.91 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 1898000 | 1761000 | 7.78 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 0 | -1446000 | 100.00 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -513000 | -2352000 | 78.19 |
| net cash used for investing activites | -513000 | -2352000 | 78.19 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 45000 | -145000 | 131.03 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 45000 | -145000 | 131.03 |
| net change in cash | -10376000 | -13087000 | 20.72 |
| cash at end of period | 15999000 | 26375000 | -39.34 |
| cash at beginning of period | 26375000 | 39462000 | -33.16 |
Net Change in Cash: Net Change in Cash increased to -10 million in 2024Q2 from -13 million in 2024Q1 representing a change of 20.72%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -10 million in 2024Q2 from -11 million in 2024Q1 representing a change of 6.46%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -10 million in 2024Q2 from -13 million in 2024Q1 representing a change of 19.49%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2024Q2 from 1 million in 2024Q1 representing a change of 100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -1 million in 2024Q2 from -2 million in 2024Q1 representing a change of 78.19%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 2 million in 2024Q2 from 2 million in 2024Q1 representing a change of 7.78%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.02 | 0.01 | 113.09 |
| net income per share | -0.26 | -0.36 | 28.82 |
| operating cash flow per share | -0.25 | -0.28 | 9.28 |
| free cash flow per share | -0.3 | -0.3 | 1.29 |
| cash per share | 0.16 | 0.42 | -61.88 |
| book value per share | 0.17 | 0.39 | -57.61 |
| tangible book value per share | 0.17 | 0.39 | -57.61 |
| shareholders equity per share | 0.17 | 0.39 | -57.61 |
| interest debt per share | 0.01 | 0.01 | 6.33 |
| market cap | 140488057.77 | 278980066.3 | -49.64 |
| enterprise value | 107967057.77 | 207791066.3 | -48.04 |
| pe ratio | -2.23 | -3.58 | 37.86 |
| price to sales ratio | 23.28 | 112.13 | -79.24 |
| pocfratio | -2.26 | -4.64 | 51.25 |
| pfcf ratio | -1.94 | -4.32 | 55.19 |
| pb ratio | 3.46 | 3.32 | 4.35 |
| ptb ratio | 3.46 | 3.32 | 4.35 |
| ev to sales | 17.89 | 83.52 | -78.58 |
| enterprise value over ebitda | -1.67 | -2.35 | 28.99 |
| ev to operating cash flow | -1.74 | -3.46 | 49.69 |
| ev to free cash flow | -1.49 | -3.22 | 53.77 |
| earnings yield | -0.45 | -0.28 | -60.93 |
| free cash flow yield | -0.52 | -0.23 | -123.18 |
| debt to equity | 0.08 | 0.03 | 150.85 |
| debt to assets | 0.05 | 0.03 | 103.75 |
| net debt to ebitda | 0.5 | 0.8 | -37.57 |
| current ratio | 2.51 | 5.34 | -52.87 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.98 | 0.74 | 33.21 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 5.3 | 14.11 | -62.44 |
| research and ddevelopement to revenue | 6.56 | 20.0 | -67.22 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.17 | -0.07 | -127.57 |
| capex to revenue | 1.74 | 1.79 | -3.12 |
| capex to depreciation | 14.88 | 9.29 | 60.26 |
| stock based compensation to revenue | 1.53 | 4.24 | -63.96 |
| graham number | 0.98 | 1.79 | -45.07 |
| roic | -1.49 | -0.93 | -60.49 |
| return on tangible assets | -0.98 | -0.72 | -36.39 |
| graham net net | 0.06 | 0.31 | -79.51 |
| working capital | 25882000 | 80032000 | -67.66 |
| tangible asset value | 40564000 | 84052000 | -51.74 |
| net current asset value | 18988000 | 73912000 | -74.31 |
| invested capital | 43172000 | 86085000 | -49.85 |
| average receivables | 0 | 0 | NaN |
| average payables | 5617000 | 5187000 | 8.29 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 29.26 | 2742.43 | -98.93 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 12.48 | 0.13 | 9273.65 |
| inventory turnover | 0 | 0 | NaN |
| roe | -1.56 | -0.93 | -67.93 |
| capex per share | 0.04 | 0.02 | 106.45 |
ROE: Return on Equity (ROE) decreased to -1.56 on 2023-12-31 from -0.93 on 2022-12-31, representing a change of -67.93%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.23 on 2023-12-31 from -3.58 on 2022-12-31, representing a change of 37.86%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.51 on 2023-12-31 from 5.34 on 2022-12-31, representing a change of -52.87%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.08 on 2023-12-31 from 0.03 on 2022-12-31, representing a change of 150.85%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| OCGN | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.0 | 0.0 | 12.47 |
| net income per share | -0.06 | -0.05 | -28.08 |
| operating cash flow per share | -0.04 | -0.04 | 6.50 |
| free cash flow per share | -0.04 | -0.05 | 19.53 |
| cash per share | 0.06 | 0.1 | -40.51 |
| book value per share | 0.07 | 0.12 | -44.09 |
| tangible book value per share | 0.07 | 0.12 | -44.09 |
| shareholders equity per share | 0.07 | 0.12 | -44.09 |
| interest debt per share | 0.01 | 0.01 | -2.94 |
| market cap | 419486786.91 | 396138259.44 | 5.89 |
| enterprise value | 410654786.91 | 376595259.44 | 9.04 |
| pe ratio | -6.86 | -8.31 | 17.36 |
| price to sales ratio | 367.65 | 390.67 | -5.89 |
| pocfratio | -42.33 | -37.39 | -13.20 |
| pfcf ratio | -40.24 | -30.6 | -31.52 |
| pb ratio | 24.78 | 13.09 | 89.31 |
| ptb ratio | 24.78 | 13.09 | 89.31 |
| ev to sales | 359.91 | 371.4 | -3.09 |
| enterprise value over ebitda | -27.61 | -31.29 | 11.74 |
| ev to operating cash flow | -41.43 | -35.54 | -16.57 |
| ev to free cash flow | -39.4 | -29.09 | -35.44 |
| earnings yield | -0.04 | -0.03 | -21.01 |
| free cash flow yield | -0.02 | -0.03 | 23.97 |
| debt to equity | 0.2 | 0.11 | 73.60 |
| debt to assets | 0.08 | 0.07 | 24.05 |
| net debt to ebitda | 0.59 | 1.62 | -63.42 |
| current ratio | 1.04 | 1.87 | -44.58 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.65 | 0.89 | -27.00 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 6.74 | 6.32 | 6.69 |
| research and ddevelopement to revenue | 7.8 | 6.73 | 15.90 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.05 | -0.22 | 76.68 |
| capex to revenue | 0.45 | 2.32 | -80.62 |
| capex to depreciation | 0.89 | 13.14 | -93.25 |
| stock based compensation to revenue | 1.66 | 1.74 | -4.22 |
| graham number | 0.3 | 0.35 | -15.38 |
| roic | -0.76 | -0.36 | -110.37 |
| return on tangible assets | -0.38 | -0.23 | -63.71 |
| graham net net | -0.03 | 0.02 | -263.45 |
| working capital | 645000 | 13948000 | -95.38 |
| tangible asset value | 16927000 | 30261000 | -44.06 |
| net current asset value | -4998000 | 8465000 | -159.04 |
| invested capital | 18119000 | 31602000 | -42.67 |
| average receivables | 0 | 0 | NaN |
| average payables | 2561000 | 2451500 | 4.47 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 34.28 | 870.34 | -96.06 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 2.63 | 0.1 | 2438.66 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.9 | -0.39 | -129.09 |
| capex per share | 0.0 | 0.01 | -78.20 |
ROE: Return on Equity (ROE) decreased to -0.90 on 2024-06-30 Q2 from -0.39 on 2024-03-31 Q1, representing a change of -129.09%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -6.86 on 2024-06-30 Q2 from -8.31 on 2024-03-31 Q1, representing a change of 17.36%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.04 on 2024-06-30 Q2 from 1.87 on 2024-03-31 Q1, representing a change of -44.58%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.20 on 2024-06-30 Q2 from 0.11 on 2024-03-31 Q1, representing a change of 73.60%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 0.04 which is lower than current price 1, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-11-14 17:40:25
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
Sentiment: Neutral
Publish Date: 2024-11-08 10:18:35
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Sentiment: Positive
Publish Date: 2024-11-08 06:45:00
Subsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025 OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trial New data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical Showcase MALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported third quarter 2024 financial results along with a general business update.
Sentiment: Positive
Publish Date: 2024-11-07 06:30:00
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P., a fund of Avenue Capital Group. Proceeds from the facility are intended for general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
Sentiment: Positive
Publish Date: 2024-10-28 06:30:00
MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an in-person Clinical Showcase on Tuesday, November 12, 2024. The event will take place from 10 a.m.-noon ET at the Nasdaq MarketSite in Times Square, New York City.
Sentiment: Positive
Publish Date: 2024-10-22 07:02:00
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 1/2 clinical trial. OCU410ST (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for Stargardt disease.
Sentiment: Positive
Publish Date: 2024-10-17 07:30:00
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Friday, November 8, 2024.
Sentiment: Positive
Publish Date: 2024-10-09 06:30:00
MALVERN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion protein consisting of tumstatin and transferrin, for treating diabetic macular edema (DME).
Sentiment: Positive
Publish Date: 2024-10-02 06:30:00
MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024 at the Arizona Biltmore in Phoenix, AZ.
Sentiment: Positive
Publish Date: 2024-09-24 07:30:00
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan's 8th Annual Genetic Medicines Conference being held September 30-October 1, 2024 in New York, New York.
Sentiment: Positive
Publish Date: 2024-09-17 02:25:58
Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA's RMAT designation and is supported by an Expanded Access Program. Ocugen's broader pipeline includes OCU410 for geographic atrophy and OCU410ST for Stargardt disease, both progressing through early trials.
Sentiment: Positive
Publish Date: 2024-09-09 06:30:00
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, “U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks.” This two-day event will take place from September 9-11, 2024 in New Delhi, India.
Sentiment: Positive
Publish Date: 2024-09-05 07:00:00
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer, Head of Research & Development, will be among the featured speakers at the 5 th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held September 10-12, 2024 in Boston, Mass.
Sentiment: Positive
Publish Date: 2024-09-03 07:30:00
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9-11, 2024 in New York, NY.
Sentiment: Positive
Publish Date: 2024-08-28 06:30:00
MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States (U.S.) and Europe.
Sentiment: Neutral
Publish Date: 2024-08-27 12:45:30
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
Sentiment: Positive
Publish Date: 2024-08-26 07:02:00
MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Health Canada provided a “No Objection Letter” to initiate the OCU400 Phase 3 liMeliGhT (pronounced “limelight”) clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).
Sentiment: Positive
Publish Date: 2024-08-20 09:00:00
SAN FRANCISCO , Aug. 20, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Ocugen, Inc. investors that the firm is investigating potential legal claims relating to an earnings restatement and possible substantial insider trading by key executives and company directors. Current shareholders are encouraged to contact the firm regarding their rights.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
